[
  {
    "ts": "2025-08-14T13:00:00+00:00",
    "headline": "U.S. mRNA Therapeutics CDMO Market to Hit Valuation of US$ 6.27 Billion by 2033 | Astute Analytica",
    "summary": "Shifting from its pandemic response origins, the market is diversifying into new vaccines and oncology. Asset-light biotechs fuel this growth, making specialized CDMOs essential partners for advancing next-generation mRNA therapies into the clinic and beyond.Chicago, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The US mRNA therapeutics CDMO market was valued at US$ 1.78 billion in 2024 and is expected to reach US$ 6.27 billion by 2033, growing at a CAGR of 15.01% during the forecast period 2025–2033. The o",
    "url": "https://finance.yahoo.com/news/u-mrna-therapeutics-cdmo-market-130000390.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "6698bad4-496c-33a6-9797-f3e08e996c4a",
      "content": {
        "id": "6698bad4-496c-33a6-9797-f3e08e996c4a",
        "contentType": "STORY",
        "title": "U.S. mRNA Therapeutics CDMO Market to Hit Valuation of US$ 6.27 Billion by 2033 | Astute Analytica",
        "description": "",
        "summary": "Shifting from its pandemic response origins, the market is diversifying into new vaccines and oncology. Asset-light biotechs fuel this growth, making specialized CDMOs essential partners for advancing next-generation mRNA therapies into the clinic and beyond.Chicago, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The US mRNA therapeutics CDMO market was valued at US$ 1.78 billion in 2024 and is expected to reach US$ 6.27 billion by 2033, growing at a CAGR of 15.01% during the forecast period 2025–2033. The o",
        "pubDate": "2025-08-14T13:00:00Z",
        "displayTime": "2025-08-14T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471",
          "originalWidth": 300,
          "originalHeight": 300,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JHwPm5XOBkH6S4g8iMmLiw--~B/aD0zMDA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471.cf.webp",
              "width": 300,
              "height": 300,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SbelUm4u7tLxgdG5STxR1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/u-mrna-therapeutics-cdmo-market-130000390.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/u-mrna-therapeutics-cdmo-market-130000390.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]